Skip to content

Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging

Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging: the MDS (Melanoma Detecting System)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02056522
Enrollment
357
Registered
2014-02-06
Start date
2016-07-31
Completion date
2018-07-31
Last updated
2020-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Lesions

Keywords

Melanoma, Skin Cancer

Brief summary

The use of MDS to access the presence of melanoma in the skin.

Detailed description

A topical agent is applied to suspicious skin lesions and imaged. The images are analyzed to provide a score that correlates with the probability for the presence of melanoma in the lesion.

Interventions

None listed

Sponsors

Orlucent, Inc
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 97 Years
Healthy volunteers
No

Inclusion criteria

* Individuals with skin lesion with one or more of the ABCDE features and recommended for a skin biopsy. * The lesion is accessible to the imaging device, with at least 1 cm of skin around the lesion that is accessible to the MDS. * Male and female ≥ 21 years old. * Subject is capable of giving written informed consent. * Primary excision.

Exclusion criteria

* The lesion is less than 1 cm from the eyes. * The lesion is on the palms of hands or soles of the feet. * Mucosal lesion. * Pregnant females. * Low study procedure compliance. * Patients who are mentally or physically unable to comply with all aspects of the study. * Undergoing chemotherapy. * Minor or legally incompetent and not able to sign the consent form. * Patient previously tested by MDS and was diagnosed with melanoma during the study.

Design outcomes

Primary

MeasureTime frame
To validate the performance of MDS28 days

Secondary

MeasureTime frame
To calculate and specify the PPV and NPV of the MDS for melanoma detection when used as an adjacent tool to visual skin examination.28 days

Other

MeasureTime frame
To further establish the safety of the MDS.28 days

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026